ACT-HIB

This brand name is authorized in Austria, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Netherlands, New Zealand, Poland, Turkey.

Active ingredients

The drug ACT-HIB contains one active pharmaceutical ingredient (API):

1
UNII FLV5I5W26R - HAEMOPHILUS INFLUENZAE TYPE B STRAIN 1482 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
 

Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease.

 
Read more about Haemophilus influenzae B

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J07AG01 Haemophilus influenzae B, purified antigen conjugated J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AG Haemophilus influenzae B vaccines
Discover more medicines within J07AG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1019584
FI Lääkealan turvallisuus- ja kehittämiskeskus 198901
FR Base de données publique des médicaments 61104024
HK Department of Health Drug Office 37568
NL Z-Index G-Standaard 13901397
NL Z-Index G-Standaard, PRK 36471
NZ Medicines and Medical Devices Safety Authority 6803
PL Rejestru Produktów Leczniczych 100224400
TR İlaç ve Tıbbi Cihaz Kurumu 8699625960022

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.